Leukotrienes and atherosclerosis: New roles for old mediators

Trends in Immunology

Volumn 25, Issue 6, 2004, Pages 315-322

  Jala, Venkatakrishna R ^a,b   Haribabu, Bodduluri ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; COLONY STIMULATING FACTOR; COMPLEMENTARY DNA; FRACTALKINE; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 8; LEUKOTRIENE; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE C 4 RECEPTOR; LEUKOTRIENE C4 DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOPONTIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; UROKINASE;

ASTHMA; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD FLOW; CARBOXY TERMINAL SEQUENCE; CELL TYPE; CHEMOTAXIS; COLITIS; DERMATITIS; DIMERIZATION; DNA MICROARRAY; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE LOCUS; HEART INFARCTION; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; LEUKOCYTE ADHERENCE; MOLECULAR CLONING; MONOCYTE; NONHUMAN; PHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; QUANTITATIVE TRAIT LOCUS; REVIEW; RHEUMATOID ARTHRITIS; SEQUENCE ANALYSIS; SEX DIFFERENCE; T LYMPHOCYTE; VASCULAR LESION;

ANIMALS; ARTERIOSCLEROSIS; HUMANS; INFLAMMATION MEDIATORS; LEUKOTRIENES; MICE; MODELS, IMMUNOLOGICAL; RECEPTORS, LEUKOTRIENE;

EID: 2342543199     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2004.04.003     Document Type: Review

References (72)

1. Dahlen S.E., et al. Leukotrienes are potent constrictors of human bronchi. Nature. 288:1980;484-486
2. Ford-Hutchinson A.W., et al. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 286:1980;264-265
3. Samuelsson B., et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 237:1987;1171-1176
4. Serhan C.N., et al. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10:1996;1147-1158
5. Bandeira-Melo C., et al. Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eiosinophil trafficking. J. Immunol. 164:2000;2267-2271
6. Bonventre J.V. Cytosolic phospholipase a2α reigns supreme in arthritis and bone resorption. Trends Immunol. 25:2004;116-119
7. Luo M., et al. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity. Proc. Natl. Acad. Sci. U. S. A. 100:2003;12165-12170
8. Fabre J.-E., et al. Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. J. Clin. Invest. 109:2002;1373-1380
9. Yokomizo T., et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 387:1997;620-624
10. Lynch K.R., et al. Characterization of the human cysteinyl leukotriene CysLT(1) receptor. Nature. 399:1999;789-793
11. Fiore S., et al. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180:1994;253-260
12. Tager A.M., Luster A.D. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot. Essent. Fatty Acids. 69:2003;123-134
13. Brink C., et al. International union of pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55:2003;195-227
14. Evans J.F. The cysteinyl leukotriene receptors. Prostaglandins Leukot. Essent. Fatty Acids. 69:2003;117-122
15. Yokomizo T., et al. A second leukotriene B-4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192:2000;421-431
16. Kamohara M., et al. Molecular cloning and characterization of another leukotriene B-4 receptor. J. Biol. Chem. 275:2000;27000-27004
17. Tryselius Y., et al. Cloning and characterization of cDNA encoding a novel human leukotriene B-4 receptor. Biochem. Biophys. Res. Commun. 274:2000;377-382
18. 4 receptor: cloning and functional characterization. J. Biol. Chem. 275:2000;40686-40694
19. Nothacker H.-P., et al. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol. Pharmacol. 58:2000;1601-1608
20. Hui Y., Funk C.D. Cysteinyl leukotriene receptors. Biochem. Pharmacol. 64:2002;1549-1557
21. Haribabu B., et al. Chemoattractant receptors activate distinct pathways for chemotaxis and secretion - role of G-protein usage. J. Biol. Chem. 274:1999;37087-37092
22. Friedrich E.B., et al. Mechanisms of leukotriene B4-triggered monocyte adhesion. Arterioscler. Thromb. Vasc. Biol. 23:2003;1761-1767
23. Subbarao K., et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler. Thromb. Vasc. Biol. 24:2004;369-375
24. Ogasawara H., et al. Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT2. Differential pharmacological properties and tissue distribution. J. Biol. Chem. 277:2002;18763-18768
25. Devi L.A. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol. Sci. 22:2001;532-537
26. Baneres J.L., Parello J. Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J. Mol. Biol. 329:2003;815-829
27. Landschulz W.H., et al. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science. 240:1988;1759-1764
28. Sjostrom M., et al. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23:2003;E37-E41
29. Lotzer K., et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 23:2003;E32-E36
30. Tager A.M., et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat. Immunol. 4:2003;982-990
31. Goodarzi K., et al. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat. Immunol. 4:2003;965-973
32. Ott V.L., et al. Mast cell-dependent migration of effector CD8+T cells through production of leukotriene B4. Nat. Immunol. 4:2003;974-981
33. Payan D.G., et al. Human T-lymphocyte subset specificity of the regulatory effects of leukotriene B4. Proc. Natl. Acad. Sci. U. S. A. 81:1984;3501-3505
34. Ariel A., et al. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-α secretion from human T cells. J. Immunol. 170:2003;6266-6272
35. Wenzel S.E. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy. 17:1997;3S-12S
36. Matsukawa A., et al. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B-4. J. Immunol. 163:1999;6148-6154
37. Dahlen S.E., et al. Lipoxins and other lipoxygenase products with relevance to inflammatory reactions in the lung. Ann. N. Y. Acad. Sci. 629:1991;262-273
38. Griffiths R., et al. Leukotriene B4 plays a critical role in the progression of collagen- induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;517-521
39. Holgate S.T., et al. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol. 111:(1 Suppl):2003;S18-S34. discussion S34-16
40. Showell H.J., Cooper K. Inhibitors and antagonists of cyclooxygenase, 5-lipoxygenase, and platelet activating factor. Gallin J.I., Snyderman R. Inflammation: Basic Principles and Clinical Correlates. 1999;1177-1193 Lippincott Williams & Wilkins
41. Wenzel S.E., Kamada A.K. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann. Pharmacother. 30:1996;858-864
42. Chen X.S., et al. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature. 372:1994;179-182
43. Goulet J.L., et al. Altered inflammatory responses in leukotriene-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 91:1994;12852-12856
44. Griffiths R.J., et al. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J. Exp. Med. 185:1997;1123-1129
45. Byrum R.S., et al. Determination of the contribution of cysteinyl leukotrienes and leukotriene B-4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A(4) hydrolase-deficient mice. J. Immunol. 163:1999;6810-6819
46. Irvin C.G., et al. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am. J. Physiol. 272:1997;L1053-L1058
47. Goulet J.L., et al. Deficiency of 5-lipoxygenase abolishes sex-related survival differences in MRL-lpr/lpr mice. J. Immunol. 163:1999;359-366
48. Goulet J.L., et al. Deficiency of 5-lipoxygenase accelerates renal allograft rejection in mice. J. Immunol. 167:2001;6631-6636
49. Haribabu B., et al. Targeted disruption of the leukotriene B-4 receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J. Exp. Med. 192:2000;433-438
50. Tager A.M., et al. BLTR mediates leukotriene B-4-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J. Exp. Med. 192:2000;439-446
51. Maekawa A., et al. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J. Biol. Chem. 277:2002;20820-20824
52. Chiang N., et al. Leukotriene B-4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 104:1999;309-316
53. Devchand P.R., et al. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J. 17:2003;652-659
54. Lusis A.J. Atherosclerosis. Nature. 407:2000;233-241
55. Steinberg D., et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924
56. Harrison K.A., Murphy R.C. Isoleukotrienes are biologically active free radical products of lipid peroxidation. J. Biol. Chem. 270:1995;17273-17278
57. Allayee H., et al. Using mice to dissect genetic factors in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23:2003;1501-1509
58. Dansky H.M., et al. A phenotype-sensitizing apoE-deficient genetic background reveals novel atherosclerosis predisposition loci in the mouse. Genetics. 160:2002;1599-1608
59. Mehrabian M., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 91:2002;120-126
60. Mehrabian M., Allayee H. 5-lipoxygenase and atherosclerosis. Curr. Opin. Lipidol. 14:2003;447-457
61. Kuhn H., et al. Amino acid differences in the deduced 5-lipoxygenase sequence of CAST atherosclerosis-resistance mice confer impaired activity when introduced into the human ortholog. Arterioscler. Thromb. Vasc. Biol. 23:2003;1072-1076
62. Dwyer J.H., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 350:2004;29-37
63. Cyrus T., et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest. 103:1999;1597-1604
64. Trebus F., et al. Transient experimental anemia in cholesterol-fed rabbits induces systemic overexpression of the reticulocyte-type 15-lipoxygenase and protects from aortic lipid deposition. Prostaglandins Leukot. Essent. Fatty Acids. 67:2002;419-428
65. De Caterina R., et al. Leukotriene B4 production in human atherosclerotic plaques. Biomed. Biochim. Acta. 47:1988;S182-S185
66. Spanbroek R., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 100:2003;1238-1243
67. Aiello R.J., et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol. 22:2002;443-449
68. Gu L., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2:1998;275-281
69. Febbraio M., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105:2000;1049-1056
70. Boisvert W.A., et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J. Clin. Invest. 101:1998;353-363
71. -/- mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111:2003;333-340
72. Combadiere C., et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 107:2003;1009-1016